The claimed invention is:

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof where:

R^1 is H;

R^2 is a substituted or unsubstituted $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_y)$cycloalkyl, $(C_3\text{-}C_9)$aryl, $(C_3\text{-}C_9)$heteroaryl, amide, amino, $(C_1\text{-}C_8)$alcohol, $(C_3\text{-}C_9)$heterocycloalkyl, $(C_1\text{-}C_8)$alkyl$(C_3\text{-}C_9)$aryl, $(C_1\text{-}C_8)$alkylamine, $(C_1\text{-}C_8)$alkylamide; or R^1 and R^2 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycloalkyl or heteroaryl;

R^3 is independently selected from the group consisting of H, $(C_1\text{-}C_8)$alkyl, halo, $(C_1\text{-}C_8)$alkoxy, sulfonyl, cyano, and keto;

n is an integer from 0-5;

with the proviso that the compound is not 3-amino-6-phenyl-pyrazine-2-carboxylic acid butylamide or 3-amino-6-phenyl-pyrazine-2-carboxylic acid (2-hydroxy-ethyl)-amide.

2. A compound of claim 1, wherein R^3 is H, bromo, chloro, cyano, methoxy, $(C_1\text{-}C_8)$alkyl-SO_2-, or $(C_1\text{-}C_8)$alkylC(=O)-.

3. A compound of claim 1, wherein n is 0-4.

4. A compound of claim 3, wherein n is 0-1.

5. A compound of formula (II):



(II)

or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof where:

R^1 is H;

R^2 is a substituted or unsubstituted (C_1-C_8)alcohol, (C_3-C_9)cycloalkyl, (C_3-C_9)heterocycloalkyl, (C_3-C_9)heteroaryl, (C_1-C_8)alkylamine, (C_1-C_8)alkyl(C_3-C_9)aryl, or (C_1-C_8)alkylamide; or R^1 and R^2 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycloalkyl or heteroaryl group;

Het is a substituted or unsubstituted heterocyclyl or heteroaryl group containing at least one heteroatom selected from N, O and S.

6. A compound of claim 5, wherein Het is a substituted or unsubstituted (C_5-C_{10})heterocyclyl or heteroaryl group containing at least one heteroatom selected from N, O and S.

7. A compound of claim 6, wherein Het is a substituted or unsubstituted furanyl, thienyl, pyridyl, or benzofuranyl group.

8. A compound of formula (III):



(III)

or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof where:

R^1 is H;

R^2 is a substituted or unsubstituted (C_1-C_8)alcohol;

Ar is a substituted or unsubstituted (C_3-C_9)aryl group;

with the proviso that the compound is not 3-amino-6-phenyl-pyrazine-2-carboxylic acid butylamide or 3-amino-6-phenyl-pyrazine-2-carboxylic acid (2-hydroxy-ethyl)-amide.

9. A compound of claim 8, wherein R^2 is a substituted or unsubstituted (C_1-C_5)alcohol.

10. A compound of claim 9, wherein R^2 is a substituted or unsubstituted (C_3-C_5)alcohol.

11. A compound of claim 8, wherein Ar is a substituted or unsubstituted naphthyl group.

12. A pharmaceutical composition comprising a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier.

13. A method of preventing or treating a TGF-related disease state in a mammal (animal or human) comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1-11 to the animal or human suffering from the TGF-related disease state.

14. A method of claim 13, wherein said TGF-related disease state is selected from the group consisting of cancer, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, intimal hyperplasia and restenosis, scleroderma, and dermal scarring.